# TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib

> **NCT04173585** · PHASE2 · COMPLETED · sponsor: **University Hospital Heidelberg** · enrollment: 50 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Gemtuzumab Ozogamicin

## Key facts

- **NCT ID:** NCT04173585
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-22
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-03-24
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04173585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04173585, "TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04173585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*